

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 6

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	01-2113

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	A1	US- 5 041 449	08-20-1991	BELLEAU ET AL.	
	A2	US- 5 047 407	09-10-1991	BELLEAU ET AL.	
	A3	US- 5 053 499	10-01-1991	KOJIMA ET AL.	
	A4	US- 5 270 315	12-14-1993	BELLEAU, BERNARD	
	A5	US- 5 294 612	03-15-1994	BACON ET AL.	
	A6	US- 5 466 806	11-14-1995	BELLEAU ET AL.	
	A7	US- 5 541 187	07-30-1996	BACON ET AL.	
	A8	US- 5 563 049	10-08-1996	KOJIMA ET AL.	
	A9	US- 5 684 164	11-04-1997	BELLEAU ET AL.	
	A10	US- 5 750 673	05-12-1998	MARTIN	
	A11	US- 5 969 116	10-19-1999	MARTIN	
	A12	US- 5 977 332	11-02-1999	MARTIN	
	A13	US- 6 100 037	08-08-2000	PHILLIPS ET AL.	
	A14	US- 6 175 008	01-15-2001	BELLEAU ET AL.	
	A15	US- 6 174 884	01-15-2001	HANING ET AL.	
	A16	US- 6 211 158	04-03-2001	SEELA ET AL.	
	A17	US- 6 225 315	05-01-2001	ELLIS	
	A18	US- 2001 0041797	11-15-2001	BELLEAU ET AL.	
	A19	US- 6 631 174	12-14-2004	BELLEAU ET AL.	
	A20	US-2001 0044441	11-22-2001	CAMPBELL ET AL.	
	A21	US- 6 350 753	02-26-2002	BELLEAU ET AL.	
	A22	US-2002 0058635	05-16-2002	AVERETT	
	A23	US- 6 407 114	06-18-2002	BUNNAGE ET AL.	
	A24	US-2002 0132754	09-19-2002	BOSS ET AL.	
	A25	US- 6 458 796	10-01-2002	HANING ET AL.	
	A26	US- 6 479 463	11-12-2002	WANG ET AL.	
	A27	US- 2003 0087918	05-08-2003	BELLEAU ET AL.	
	A28	US- 6 903 224	06-07-2005	BELLEAU ET AL.	
	A29	US- 7 067 507	06-27-2006	PULLEY ET AL.	
	A30	US- 2004 0185459	09-23-2004	OTSUKA ET AL.	
	A31	US-2004 0220188	11-04-2004	BELL ET AL.	
	A32	US- 2004 0254201	12-16-2004	BELLEAU ET AL.	
	A33	US- 7 122 693	10-17-2006	BELLEAU ET AL.	
Examiner Signature				Date Considered	

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet **2** of **6**

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	01-2113

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No.	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A39	US-2007 0037977	02-15-2007	BELLEAU ET AL.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document Country Code* - Number* - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
	B1	EP-0 286 028	10-12-1988	BOEHRINGER MANNHEIM GMBH		B4
	B2	DE-4 004 558	09-27-1990	SANYO KOKUSAKU PULP CO		A3
	B3	EP-496 617	07-29-1992	GENSIA PHARMA		
	B4	CA-1 311 201	12-08-1992	BOEHRINGER MANNHEIM GMBH		
	B5	WO-94 14802	07-07-1994	BELLEAU PIERRETTE & HF		
	B6	WO-94 17803	08-18-1994	GENSIA INC		
	B7	EP-0 626 387	11-30-1994	CIBA GEIGY AG		
	B8	EP-0 679 657	11-02-1995	CIBA GEIGY AG		A10
	B9	WO-96 28429	09-19-1996	SANOFI WINTHROP INC		
	B10	WO-97 16455	05-09-1997	CHONG KUN DANG CORP		
	B11	WO-97 46569	12-11-1997	CIBA GEIGY AG		
	B12	WO-98 00434	01-08-1998	CIBA GEIGY AG		
	B13	WO-98 16184	04-23-1998	ICN PHARMACEUTICALS		
	B14	JP-11-501923	02-16-1999	SANOFI WINTHROP INC.		
	B15	EP-0 995 751	04-26-2000	PFIZER		A23
	B16	CA-2 357 146	07-13-2000	INCYTE PHARMA INC		
	B17	WO-2000 043394	07-27-2000	USTAV EXPERIMENTALI BOTANIKI AV CR		
	B18	WO-2001 05758	01-25-2001	NPS ALLELIX CORP		
	B19	WO-2001 060315	08-23-2001	BIOCHEM PHARMA INC.		
	B20	JP- 2001 514538	09-11-2001	BAYER AG		A15
	B21	WO-2001 077075	10-18-2001	INOTEK CORP		
	B22	WO-2002 16348	02-28-2002	ASTRAZENECA AB		
	B23	WO-2002 057425	07-25-2002	MERCK & CO INC		
	B24	JP-2002 523507	07-30-2002	Bayer AG		A25
	B25	WO-2002 074774	09-26-2002	PFIZER LTD		
	B26	WO-2002 086160	10-31-2002	MITSUBISHI RAYON CO		A30

Examiner
Signature

Date
Considered

*EXAMINER Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	01-2113

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†6
		Country Code 2 - Number 3 - Kind Code 4 (if known)					
	B27	WO-2003 011925		02-13-2003	PPG IND OHIO INC		
	B28	WO-2003 022859		03-20-2003	EPOCH BIOSCIENCES INC		
	B29	CA-2 466 824		05-08-2003	PFIZER		
	B30	CA-2 238 211		12-09-1998	GIVAUDAN ROURE INT		
	B31	WO-2003 037432		05-08-2003	PFIZER PROD INC		
	B32	WO-2003 072757		09-04-2003	BIOTA INC		
	B33	WO-2003 099840		12-04-2003	ISIS PHARMACEUTICALS INC		
	B34	CA-2 496 194		03-04-2004	BAYER HEALTHCARE AG		
	B35	DE-102 38 722		03-11-2004	BAYER AG		
	B36	CA-2 496 292		04-01-2004	BAYER HEALTHCARE AG		
	B37	CA-2 496 308		04-01-2004	BAYER HEALTHCARE AG		
	B38	WO-2004 046331		06-03-2004	IDENIX CAYMAN LTD		
	B39	EP-1 460 077		09-22-2004	JORDANIAN PHARMACEUTICAL MFG		
	B40	JP-2004 536933		12-09-2004	PPG IND OHIO INC		
	B41	WO-2004 108139		12-16-2004	AREXIS AB		
	B42	WO-2004 002999		01-08-2004	IDENIX CAYMAN LTD		
	B43	WO-2005 051944		06-09-2005	UNIV CONNECTICUT		
	B44	JP-2005 531549		10-20-2005	BAYER CROSCIENCE AG		
	B45	JP-2006 201272		01-12-2006	TAMURA SEISAK		
	B46	JP-2006 503051		01-26-2006	BAYER AG		
	B47	WO-2006 084281		08-10-2006	MILLENNIUM PHARM INC		
	B48	WO-2006 091905		08-31-2006	GILEAD SCIENCES INC		
	B49	GB-937 724		09-25-1963	CIBA LTD		
	B50	WO-2006/078455		07-20-2006	ARENA PHARM INC.		
	B51	WO-2007 025043		03-01-2007	IDENIX PHARMACEUTICALS INC		
	B52	WO-2007 046747		04-26-2007	ASTRAZENECA AB		
	B53	WO-2008 005542		01-10-2008	GILEAD SCIENCES INC		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. † Applicant's unique citation designation number (optional). ‡ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. † Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ‡ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number 10/524,956
 Filing Date December 15, 2005
 First Named Inventor Martin Hendrix
 Art Unit 1624
 Examiner Name Susanna Moore
 Attorney Docket Number 01-2113

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	B54	WO-2008	055959	05-15-2008	GALAPAGOS N V		
	B55	WO-2008	100447	08-21-2008	GILEAD SCIENCES INC		
	B56	WO-2008	104077	09-04-2008	METHYLGENE INC		
	B57	WO-2008	139293	11-20-2008	PFIZER		
	B58	WO-2009	068617	06-04-2009	BOEHRINGER INGELHEIM INT		
	B59	WO-2009	121919	10-08-2009	BOEHRINGER INGELHEIM INT		
	B60	WO-2010	028214	03-11-2010	BOEHRINGER INGELHEIM INT		
	B61	WO-2010	112437	10-07-2010	BOEHRINGER INGELHEIM INT		

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T ²
	C1	Accessed on December 18, 2008, http://en.wikipedia.org/wiki/Amnesia		
	C2	Accessed on December 18, 2008, www.mentalhealth.org.uk/information/mental-health-a-z/dementia		
	C3	BARGER ET AL., "Role of cyclic GMP in the Regulation of Neuronal Calcium and Survival by Secreted Forms of Beta-Amyloid Precursor," J of Neurochem, 1995, Vol. 64, No. 5, pp. 2087-2095		
	C4	BYRN ET AL., Solid State Chemistry of Drugs, 1999, Second Edition, Chapter 11, pp. 232-247		
	C5	Chem Abstracts Service, Database Accession No. ALB-H01677136, Database Chemcats, 2007, XP002555399		
	C6	DÖRWALD ET AL., "Side reactions in organic synthesis," A Guide to Successful Synthesis Design, 2005, 4 pages		
	C7	EBERT ET AL., "Scopolamine model of dementia: electroencephalogram findings and cognitive performance," Europ J of Clinical Investigation, 1998, Vol. 28, No. 11, pp. 944-949		
	C8	FRANCIS ET AL., "Glutamatergic systems in Alzheimer's disease," International Journal of Geriatric Psychiatry, 2003, Vol. 18, p. S15-21		
	C9	FRANCIS ET AL., "Cortical Pyramidal Neuron Loss May Cause Glutamatergic Hypoactivity and Cognitive Impairment in Alzheimer's Disease: Investigative and Therapeutic Perspectives," Journal of Neurochemistry, 1993, Vol. 60, No. 5, pp. 1589-1604		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kind Code of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 5 of 6

Complete if Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	01-2113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C10	HARB ET AL., "Pyrazoles as building blocks in heterocyclic synthesis," Chemical Papers, 2005, Vol. 59, No. 3, pp. 187-195, XP002498868	
	C11	Last accessed July 15, 2010http://www.nlm.nih.gov/medlineplus/ency/article/000746.htm	
	C12	HUNG ET AL., "A high-yielding synthesis of monalkylhydrazines," Journal of Organic Chemistry, 1981, Vol. 46, pp. 5413-5414	
	C13	International Search Report of PCT/EP2003/08880 dated April 1, 2004, International Filing Date: August 11, 2003, International Publication No. WO 2004 026286	
	C14	MARKWALDER, J. A. ET AL., "Synthesis and Biological Evaluation of 1-Aryl-4,5-dihydro-1H-pyrazolo[3,4-d]pyrimidin-4-one Inhibitors of Cyclin-Dependent Kinases," J of Med Chemistry, 2004, Vol. 47, pp. 5894-5911, XP002399637	
	C15	PODRAZA ET AL., "Reductive Cyclization of Ketoesters Utilizing Sodium Cyanoborohydride: Synthesis of γ - and δ -lactones," J of Heterocyclic Chem., 1987, Vol. 24, pp. 293-295	
	C16	PRICKAERTS ET AL., "Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic gmp levels in the rat," Neuroscience, 2002, Vol. 113, No. 2, pp. 351-361	
	C17	PRICKAERTS ET AL., "Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: Effects of 7-nitroindazole and zaprinast," Europ J of Pharmacology, 1997, Vol. 337, pp. 125-136	
	C18	PUZZO ET AL., "Amyloid-Beta Peptide Inhibits Activation of the Nitric Oxide/Cgmp/Camp-Responsive Element-Binding Protein Pathway during Hippocampal Synaptic Plasticity," The Journal of Neuroscience, 2005, Vol. 25, No. 29, pp. 6867-6867	
	C19	REID ET AL., "Role of Phosphodiesterase isoenzymes in the control of renin secretion: effects of selective enzyme inhibitors," Current Pharmaceutical Design, 1999, Vol. 5, No. 9, pp. 725-735	
	C20	REYMANN ET AL., "The late maintenance of hippocampal LTP: Requirements, phases, 'synaptic tagging', 'late-associativity' and implications," Neuropharmacology, 2007, Vol. 52, pp. 24-40	
	C21	SCHMIDT ET AL., "Pyrazolo[3, 4-d] pyrimidin-nucleoside," Chemische Berichte, 1977, Vol. 110, pp. 2445-2455	
	C22	SKIPPER ET AL., "Structure-Activity Relationships Observed on Screening a Series of Pyrazolopyrimidines against Experimental Neoplasms," Cancer Research, 1957, Vol. 17, pp. 579-586	
	C23	TIMBERLAKE ET AL., "Chemistry of Hydrazo-, Azo-, and Azoxy Groups," Patai, 1975, Chapter 4	
	C24	UGARKAR ET AL., "Synthesis and antiviral/antitumor activities of...", Journal of Medicinal Chemistry, 1984, Vol. 27, No. 8, pp. 1026-1030	
	C25	VAN STAVEREN ET AL., Journal of Neurocytology, 2002, Vol. 31, pp. 729-741	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST 3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. Applicant is to place a check mark here if English language. Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 6 of 6

Complete If Known

Application Number	10/524,956
Filing Date	December 15, 2005
First Named Inventor	Martin Hendrix
Art Unit	1624
Examiner Name	Susanna Moore
Attorney Docket Number	01-2113

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C28	WANG ET AL. "Identification and characterization of a new human type 9 cGMP-specific phosphodiesterase-splice variant (PDE9A5) Different tissue distribution and subcellular localization of PDE9A variants," Gene, 2003, Vol. 314, no. 15-27	
Examiner Signature	Date Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing the burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.